Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330143 | 0.84 | PDCD1 (0.36) | CHKAPDCD1CD274HDAC2BTK | |
| SCHEMBL1436053 | 0.79 | PDCD1 (0.34) | CHKAPDCD1CD274HDAC2BTK | |
| SCHEMBL9386326 | 0.75 | HTR2A (0.37) | CHKAPDCD1CD274HDAC2ROCK2 | |
| SCHEMBL3535533 | 0.70 | CHKA (0.41) | CHKAPDCD1CD274HDAC2ROCK2 | |
| SCHEMBL15544410 | 0.70 | ALDH1A1 (0.38) | CHKAPDCD1CD274HDAC2ROCK2 | |
| SCHEMBL15012213 | 0.70 | CHKA (0.45) | CHKAHDAC2ROCK2ROCK1GCK | |
| SCHEMBL330155 | 0.70 | TSHR (0.46) | CHKAHDAC2ROCK2ROCK1GCK | |
| SCHEMBL15240655 | 0.69 | TSHR (0.49) | CHKAHDAC2ROCK2ROCK1GCK | |
| SCHEMBL30492984 | 0.69 | PDCD1 (0.36) | PDCD1CD274HDAC2 | |
| SCHEMBL2697488 | 0.69 | PDCD1 (0.39) | PDCD1CD274HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | disclosed |
| US-6861440-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | CHKA 2779/4885PDCD1 1285/4885CD274 1969/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | CHKA 2701/4885PDCD1 1830/4885CD274 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.